CDC Transcript: First case of Middle East Respiratory Syndrome Coronavirus infection (MERS) in the United States
Press Briefing Transcript
May 2, 2014 at 3:00 PM ET
OPERATOR: Welcome and thank you all for holding. I would like to remind all parties that your lines are on a listen-only mode until the question and answered segment of today’s conference. This call is being recorded. If you have any objections, please disconnect at this time. I will now turn it over to Tom Skinner for opening remarks.
TOM SKINNER: Thank you all for joining us as we discuss the first case of Middle East Respiratory Syndrome Coronavirus infection (MERS) in the United States. Today we have with us, Anne Schuchat, who is the director of the National Center for Immunization and Respiratory Diseases here at CDC. She will provide some opening remarks and then when we get to your questions; she’s going to be joined by Ms. Pamela Pontones, who is the state epidemiologist for the Indiana State Department of Health. Now I would like to turn the call over to Dr. Anne Schuchat.
ANNE SCHUCHAT: Thank you, Tom and thank you everyone for joining us today. I want to provide you with some information on a rapidly evolving situation. The first confirmed imported case of Middle East Respiratory Syndrome Coronavirus, known as MERS-CoV, has been reported in the United States. The patient, a healthcare provider, recently travelled from Saudi Arabia where outbreaks of MERS are occurring. The patient is currently in a hospital in Indiana. The patient is isolated, in stable condition, and being well-cared for. The Indiana public health laboratory tested specimens from the person using MERS-CoV testing kits developed by CDC, and today CDC confirmed the test results in our laboratory. CDC is working closely with the Indiana state health department and hospital to rapidly respond to and investigate this situation to help prevent the spread of the virus.
MERS-CoV is a virus that is relatively new to humans and was first reported in Saudi Arabia in 2012. Most people who have been confirmed to have MERS-CoV infection developed severe acute respiratory illness, with fever, cough, and shortness of breath. As of today, including this importation into the U.S. 252 people in 12 countries have been confirmed to have MERS-CoV infection; 93 of these people have died. Based on the information we have so far, people with pre-existing health conditions (comorbidities) or weakened immune systems may be more likely to become infected with, or have a severe case of, MERS-CoV.
So far, all MERS cases have been linked to six countries in or near the Arabian Peninsula.
Since March 2014, there has been an increase in the number of cases reported from Saudi Arabia and United Arab Emirates. The reason for this increase in cases is not yet known and public health investigations are ongoing.
There is no available vaccine or specific treatment recommended for MERS-CoV. We do not know where the virus came from or exactly how it spreads. In some countries, the virus has spread from infected people to others through close contact. However, there is currently no evidence of sustained spread of MERS-CoV in community settings. The virus has spread in hospitals though; the largest reported outbreak to date occurred April through May 2013 in eastern Saudi Arabia and involved 23 confirmed cases in four healthcare facilities.
CDC has been working with partners to better understand the risks of this virus, including the source, how it spreads and how infections might be prevented. In this interconnected world we live in, we expected MERSCo-V to make it to the United States. We enhanced surveillance and laboratory testing capacity in states to detect cases, we developed guidance and tools for health departments, we provided recommendations for healthcare inspection control and other measures to prevent disease spread. We provided guidance for flight crews, ems units and customs and border protection officers about reporting ill travelers to CDC. We disseminate up to date information to the public, international travelers and our public health partners. Let me share some more information with you about the first MERS patient in the United States and what we are doing now in collaboration with the hospital and state public officials to respond. On April 24 the patient traveled by plane from Saudi Arabia to London, England and from London to Chicago, Illinois. The patient took a bus from Chicago to Indiana. On the 27 of April, the patient began to experience respiratory symptoms including shortness of breath, coughing and fever. He went to the hospital on April 28 and admitted on that same day. The patient is being well cared for and is isolated. He is currently in stable condition. Because of the patient’s symptoms and travel history, Indiana public health officials tested for MERS-CoV. The Indiana state public health laboratory and CDC confirmed MERS-CoV infection in the patient this afternoon.
The lab and CDC have both confirmed MERSCo-V infection. CDC and the state health department do not yet know how the patient became infected, how many people have had close contact with the patient and whether they have become ill. We do know that many healthcare providers and workers in the hospitals have varying levels of contact with the patient. Indiana hospital is using full precaution. Standard contact and airborne to avoid exposure within the hospital and among healthcare personnel and other people interacting with the patient as is recommended by the CDC. As part of the prevention and control measures, officials are reaching out to provide guidance about monitoring their health. The first U.S. importation represents a very low risk to the broader general public. Then in some countries, there has been limited spread of the virus from person to person through close contact such as caring for or living with an infected person. However, the virus has not shown the ability to spread easily from person to person in community setting. It is very concerning that the virus has spread in hospitals and we should not be surprised if additional cases are identified among the healthcare providers who had close contact with this patient before the patient was isolated and special precautions were implemented.
People will understandably be concerned by this news and want to know what they should do. CDC advises that people help protect themselves by washing hands often, avoiding close contact with people who are sick, avoiding touching your eyes, nose, and mouth with unwashed hands and disinfecting frequently touched surfaces. We don’t know exactly how this virus spreads but we encourage people to take these common steps. At this time, CDC does not recommend that anyone change travel plans. People who develop a fever or cough or shortness of breath within 14 days after traveling from countries in or near the Arabian Peninsula should see a healthcare professional and mention their recent travel. While sick they should stay home from work or school to reduce spreading illness to others. Others who should monitor their symptoms include those who have close contact with someone who has a fever and cough or shortness of breath after the other person has recently traveled to another country in or near the Arabian Peninsula. Those are the two groups that need to take special attention about their symptoms.
Healthcare providers should be aware of– after 14 days of traveling from countries in or near the Arabian Peninsula. They should contact their state or local health department and collect appropriate specimens. We have great guidance on our website. The introduction of MERSCo-V is another reminder that diseases are just a right of way. MERS is now in our heartland. Strong public health symptoms to rapidly respond and detect are critical to finding and preventing unnecessary spread of disease. This situation is very fluid. We expect to learn much more in the coming days. Our guidance and recommendations may change as the situation evolves. We will share updated information through additional press conferences and through the CDC and Indiana department of health website. Now I would like to turn things back over to Tom and answer the questions that you may have.
TOM SKINNER: I think we’re ready for questions, please.
OPERATOR: Certainly. At this time to ask a question on the phone lines, please depress star one and record your name when prompted. Star one, please. Our first question today comes from Miriam Falco. Your line is open. Please state your affiliation.
MIRIAM FALCO: I’m from CNN medical news. Thanks for taking the questions. You said the patient was in stable condition. What does that really mean? And how infectious was this patient on the plane? On the bus, and in the hospital?
ANNE SCHUCHAT: Let me begin with the answer, the patient is requiring oxygen support at this time and the patient is generally stable. The patient isn’t requiring a ventilator for respiratory support. The patient is getting excellent care in Indiana. In terms of the airplane, it’s very important to say that at this time in this investigation, we are approaching this with an abundance of caution. And so that assuring that we notify contacts through the conveyances that the patient was on and those close contacts in the healthcare facility or family is really being taken out of an abundance of caution. We have no information at this time about spread in any of those settings but we want to make sure and alert people about the potential risk. As a reminder, this virus has been exported from the Arabian Peninsula to other countries. In those settings, there was limited if any spread but the spread that happened did include others in the healthcare settings or in the family in terms of the airplane and so forth, we’re out of an abundance of caution want to assure that we’re following up with those contacts. Next question Please.
OPERATOR: Our next question comes from Mike Stobbe.
MIKE STOBBE: Hi, it’s Mike from the Associated Press. Thanks for taking my question. You said that the patient is a healthcare provider. Could you be more specific? A physician? Could you say that the gender and the age and did that person have a pre-existing condition? You mentioned pre-existing condition.
ANNE SCHUCHAT: Sure, Mike. Thanks for that question. As you can imagine, protecting the information of an individual in an investigation like this is very important. What I can tell you is that the patient is a healthcare provider who was providing healthcare while in Saudi Arabia. The additional details we’re really trying to protect the individual and that person’s family. Next question, please?
OPERATOR: Our next question comes from Jane Baranowski.
JANE BARANOWSKI: This is Jane from NBC. I’m wondering if you are releasing the name of the airline or bus line this person was on to warn other passengers?
ANNE SCHUCHAT: Thank you for that question. Sometimes we do need to put a very broad alert out. We are working closely with the department of homeland security and the airline industry so that we can direct the focus in a more targeted way to the people who actually were on the airline. So we don’t anticipate needing to do a broad alert about airlines at this point but have had very good collaboration with the industry right now. We prefer that because it can focus the greatest attention on the people who do need to be contacted. As you know sometimes we do need to go a bit wider. So we are not releasing that information at this time.
I think our next question and I want to clarify, I have been told if people have a follow up question, they’re allowed to? I guess if you have a follow up, you have probably already disconnected.
JANE BARANOWSKI: I do, what is the incubation period before the symptoms start to show?
ANNE SCHUCHAT: We think about five days between infection and when you start to be symptomatic. We have that 14 day period after travel. There are some people; there are just a few people that have that longer tail. So again out of an abundance of caution, we have got that 14 day period in with the travel history. But most of the patients that have clear cut exposure to someone else have become ill within five days. Thank you for that question. Next question?
OPERATOR: One moment, please. Once again, if parties would please press star one to ask a question. Star one to ask a question. Our next question comes from Michael Caldwell.
MICHAEL CALDWELL: This is Michael Caldwell, ABC News. I wonder if there is any plans to do background surveillance for the workers in the hospital? The case fatality rate here seems very high but I recall when West Nile Virus started we thought the case fatality rate was high and we eventually learned it was not as bad as we thought. I’m wondering where we are with that.
ANNE SCHUCHAT: Thank you. Some of the reports coming out of the investigation in the region suggest that there are some asymptomatic patients. Some people have been followed up as contacts in the Middle East and are found to be without symptoms but have a positive test. There is a very active investigation in the facility and working closely with the Indiana health department and the details are still being worked out. When there is a new infection like this about which little is known, it can be very important to learn as much as possible quickly so that we can improve our guidance and our protocols. So I think that this particular situation is one where we really hope to be able to refine the guidance that we give based on additional information gained in the first several days. That’s a chance for me to remind people that today we may have certain guidance and in the future it may change as we learn more and we realize that we can be a little bit more relaxed or need to be a little more strict. But at this point, we do know there have been people identified in other countries who have the virus identified through the chain reaction test who did not have any symptoms. That case fatality rate of about a third or 30 percent or so is based on the symptomatic patients. So there is a lot more to learn about this virus that is relatively new. Did you have a follow up?
MICHAEL CALDWELL: No, but it does give me some sense that the case fatality rate may be a lot less than we’re noting right now.
ANNE SCHUCHAT: I think that is possible. But I do want to say that for respiratory viruses that have symptoms this is a very severe clinical presentation. To have about a third of people with any symptoms dying, of course we look over time. We have been tracking that new virus and the fatality ratio may change but we have been looking at this particular virus since 2012. As I think I mentioned we’re seeing the clinical illness in people who are older with underlying medical conditions and we’re seeing about a third of them die from the virus. It’s a very serious virus. We hope to learn much more but we want to take this very seriously and not assume that it’s a mild issue. But again, things can change. That’s what we know now based on about two years of people investigating this in several countries. Next question?
OPERATOR: Our next question comes from Rob Stein.
ROB STEIN: It’s RobStein from National Public Radio. Thanks for taking my call. Can you tell us where in Indiana this patient is and anything more about any of the– anybody else on the plane or the bus or anybody else that this person has come in contact with shown any symptoms yet?
ANNE SCHUCHAT: Let me begin by saying we are trying to allow the investigation to go forward and the facility to respond locally. We aren’t aware now of anyone else with confirmed illness. We have a very active investigation on. I think I would say it’s way too early for us to breathe a sigh of relief that no one else is ill and we will be actively investigating in the groups that I mentioned. I think that the doctor may want to say more but in general we would really like to keep this at the high level rather than on the facility. Next question?
ROB STEIN: I’m sorry. Can I follow up?
ANNE SCHUCHAT: Yes, I’m sorry.
ROB STEIN: You’re saying that you’re not saying anything about where in Indiana this patient is? And are you saying that you some other folks might have gotten infected?
ANNE SCHUCHAT: No, no. Let me be very clear. We do not have reports of any other patients ill with the MERScoronavirus in this investigation. But it’s a very active investigation and very early. We only confirmed the virus this afternoon and we are just beginning to look at others. But this is not a telebriefing based on a cluster if illness in the United States. This is a single patient who has imported the virus and is ill here. We are trying to protect the specifics of the location so that is why I am not mentioning that here. That is pretty standard protocol for this kind of thing. But to say that we will update regularly and if there are additional cases, that is the type of reason that we would make updates. At this point, people are working very actively to try to understand whether others are ill and they are alerting people to look for signs and symptoms and they are also letting the clinical community know what they need to do in terms of evaluating those patients and making sure that people who do develop symptoms are isolated and not able to spread further. We don’t have any confirmed illness of the MERS coronavirus beyond a single case that I am describing at this point. So, sorry if I wasn’t clear about that. Next question?
OPERATOR: One moment, please. Our next comes from Betsy McKay. Your line is open and please state your affiliation.
BETSY MCKAY: Hi, it’s Betsy McKay from the Wall Street Journal. Dr. Schuchat, I apologize, I’m talking from a cell phone so if the reception is terrible, I apologize. I missed some of what you said earlier. So if I could just ask you to clarify, did you say the person who is a healthcare provider was given healthcare in Saudi Arabia or actually providing healthcare in Saudi Arabia? Is this your assumption or do you have knowledge that this patient probably got infected in a hospital or healthcare setting in Saudi Arabia? That’s where they got infected?
ANNE SCHUCHAT: Thank you. The person was providing healthcare in Saudi Arabia and was not ill in Saudi Arabia. The person developed symptoms in the United States. The assumption is the person acquired the illness in Saudi Arabia. We can’t confirm that it is from the hospital or the healthcare facility and that would be part of an active investigation. We know there is quite a bit of disease in Saudi Arabia right now that is under investigation. Next question, please?
BETSY MCKAY: Can I ask one quick follow up.
ANNE SCHUCHAT: Sorry. Sure. Go ahead.
OPERATOR: I’m sorry. We lost her connection.
ANNE SCHUCHAT: Okay, all right. Let’s keep going. I know we have a number of others. Hopefully everyone’s questions will get answered through someone else. Next question?
OPERATOR: Amy Birnbaum, CBS News, your line is open.
AMY BIRNBAUM: I’m sorry. I missed her question. I just wanted to follow up and ask was that healthcare worker working particularly with MERS, helping out in any sense with patients who had MERS, given that I know there has been healthcare workers who have gone over specifically to investigate that outbreak. Thank you.
ANNE SCHUCHAT: We don’t have that information at this time.
AMY BIRNBAUM: Thank you.
ANNE SCHUCHAT: Next question?
OPERATOR: Next question comes from Lena Sun, Washington Post. Your line is open.
LENA SUN: Hi. Thanks for taking the question. Can you clarify how far along are you, are folks in contacting the people who were on the plane and the bus and I assume the hospital where this patient is? It would be easier to, you know, to check. But where are we in that process?
ANNE SCHUCHAT: We’re very early in that process. This is an active investigation. We really just got the laboratory confirmation this afternoon. And you know, at CDC and in public health in general we’re committed to tell you what we know when we know it. So that is actively happening right now and we will update as we learn more from the investigation.
LENA SUN: So can I just follow up, then? Does that mean you were waiting to get the laboratory confirmation from CDC before you had the airline reach out to the people on the plane to say, okay, you know, how close were you sitting to this person in the seat? Or has that already been started?
ANNE SCHUCHAT: Let me clarify, there are many things that have been happening simultaneously. And this is very active. So we didn’t wait until we contacted every single person before we alerted the media and the general public. We have initiated many things in the past day.
LENA SUN: The other follow up question that I had is do you know whether this person was in contact with any camels?
ANNE SCHUCHAT: That’s a great question and I don’t know the answer to it. I don’t believe we have an animal exposure confirmed at this point but thank you for the question. Next question, please?
OPERATOR: Beth Galvin, your line is now open and please state your affiliation.
BETH GALVIN: Hi, I’m with Fox 5 Atlanta. Thank you very much for talking to us on this short notice today. I want to, if you could, a little bit talk about the MERS virus, how contagious it is and just what level alert is the CDC on with this case here in the U.S.?
ANNE SCHUCHAT: The MERS virus is of great concern because of the virulence. We have seen clinical respiratory illness that can be fatal up to a third of the time. On the other hand it has not yet shown the ability to be easily spread or transmitted in the community. We are not aware yet of confirmed community transmission. In healthcare facilities with good infection control practices, we don’t expect substantial transmission of this virus. And our focus, though, is in the healthcare context before it’s recognized that a person may have this illness, whether there was unprotected exposure to it. So we don’t have a sense right now that this is very easy to spread but out of an abundance of caution we are really focusing in on the healthcare contacts and the close contacts because we don’t want to take any chances. Next question?
OPERATOR: One moment. Our next question comes from Caleb Hellerman. Your line is open and please state your affiliation.
CALEB HELLERMAN: Hi it’s Caleb Hellerman, CNN. Thanks for taking the question. One thing, you have been talking about matters of days. I wonder if you could expand a little bit more on the time line of when this person was in The Kingdom and when they might have come back and was it in April or any more you can say to pin that down?
ANNE SCHUCHAT: The person traveled on April 24th from Saudi Arabia to London and then on to Chicago, Illinois. And so, they were in The Kingdom before the 24th. I don’t have the details of how long but I believe it was, you know, a substantial period. And so they have been in the United States since April 27th, and were admitted to a hospital on the 28th of April. So it’s relatively soon since this person returned to the United States and we’re closely looking at the contacts since they have returned here. Of course in these situations, we’re in close contact with our international partners who are doing other parts of this investigation. And of course, many countries are investigating suspect MERS as they have been since the virus emerged in 2012. Did you have a follow up?
CALEB HELLERMAN: A quick follow up. You talked about sort of the level of how contagious or transmissible this might be. Could you be more specific about what constitutes the kind of precautions in a healthcare setting that you think would make you not worried about transmission and maybe those weren’t being taken where she was?
ANNE SCHUCHAT: No, no. We think that the care was very good where the patient has been—
CALEB HELLERMAN: Or where she got infected.
ANN SCHUCHAT: The number of steps that can happen in a healthcare facility depend on what type of transmission you expect. There is something called contact and droplet and airborne transmission. And basically for the general public, people may need to wear masks around a patient. You may want to put them in a room where the airflow is protected and doesn’t spread. There is physical barriers that you can set up. Certainly we do standard precautions for everyone in terms of hand washing and protection around bodily fluids. This is a fairly medically technical set of issues but I would just say that we have no reason to think that there was inadequate care for this patient and that at this point with the suspicion and now confirmation, extreme measures are being taken to make sure there is no exposure that is unprotected to this patient. Next question?
CALEB HELLERMAN: Thank you.
OPERATOR: Bob Roos, your line is open. Please state your affiliation.
BOB ROOS: I’m with CIDRAP News. Thanks for taking my question. Can you say anything about where in Saudi Arabia the person was working? I know Riyadh was mentioned. Was the patient working in Delta by any chance?
ANNE SCHUCHAT: The information that we have is that the patient was working in Riyadh and that’s where they flew out of. Did you have a follow up?
BOB ROOS: No. Earlier someone asked what kind of healthcare provider the person was and I guess you can’t say any more about that correct?
ANNE SCHUCHAT: That’s right. Just that the person was working in a healthcare facility.
BOB ROOS: All right. Thank you.
ANNE SCHUCHAT: Sure, next question.
OPERATOR: Molly McCray you line is open and please state your affiliation.
MOLLY MCCRAY: I’m with KPIX out of San Francisco. I’m just wondering. You say the first case of MERS was reported in 2012 and you’ve an increase in March of 2014. Are you guys actively tracking if this virus is mutating at all? Is the CDC involved in that? Do you have any ideas why you have this surge in 2014?
ANNE SCHUCHAT: Thank you for that excellent question. There has been an increase in cases since March of this year. We actually did have more cases in the spring of last year as well. So there’s some question of whether the factors that lead to MERS may have a seasonal pattern. But of course another question that emerged with these last several weeks of cases whether there’s been a change in the virus to make it more easily transmissible. There is one isolate of the virus that was collected recently from a patient in Saudi Arabia that was sequenced and reported and there had not been, according to that report, changes in the virus that suggested any kind of mutation. So based on the sequence of one viral isolate recently, we haven’t seen changes. We will continue to monitor the situation. As you know with viral outbreaks, that’s something that is very important to keep a look out on. With the SARS virus 10 years ago, 11 years ago, we do believe there was a change in the virus that led to more explosive transmission. We will continue to look at that but we don’t have data to confirm that has happened.
MOLLY MCCRAY: May I have a follow up? I just wanted to find out how you working with your, you know, other entities, I guess in the Arabian peninsula in tracking this and taking a look at what is going on with the virus. Who are you guys working with? Is it just the CDC doing this?
ANNE SCHUCHAT: Not at all. The World Health Organization has really pulled together the different countries. We have both international partnerships that are multilateral such as through the World Health Organization and bilateral as well. So the CDC has done some investigations in the region. Other countries have done their own investigations or invited experts from other places. So this is, you know, in 2014, these new diseases are just a plane ride away, it’s really important that we cooperate internationally and that’s been absolutely vital with the MERS response. That’s a lesson that we have been learning over and over as we really try to strengthen global health security worldwide. We need every country to be strong and we need to work together effectively and we’re doing that right now. Did you have a follow up?
OPERATOR: We can go on to Allison Wyckoff your line is open and please state your affiliation.
ALLISON WYCKOFF: Hi this is Allison Wyckoff with AAP News with the American Academy of Pediatrics. And Dr. Schuchat, are there any cautions specific to children that you would like to emphasize that could be helpful to pediatricians or parent?
ANNE SCHUCHAT: We really have general precautions rather than specific to young children. I know that young children often have fever and respiratory symptoms. But the key here is, is there a history of travel within the past 14 days to the Arabian peninsula or contact with someone? And then they should alert their clinician about the travel or contact. The other thing to say is while the age range in this illness so far is very vast. I think the youngest reported case was two years old, but the median age of the case is around 60 years of age. There have been some young people, some children, some others, but the cases tend to be middle-aged or I believe it’s 51, not 61. So 51 is the median age. So it’s middle-aged people on average but there have been very young and much more elderly folks. I would just say for pediatricians, all of those kids with the high fever and respiratory symptoms, ask a travel history. The emerging respiratory viruses really need a travel history to raise suspicion. Um, next question, I think we have time for two more questions.
OPERATOR: Next we have Emily Gertz, you line is open and please state your affiliation.
EMILY GERTZ: Hi, I’m Emily Gertz with Popular Science. Doctor, can you describe what the treatment is generally and if it’s any different the treatment being provided for this woman in the states?
ANNE SCHUCHAT: The treatment for MERS coronavirus is a non-specific. That means that we treat the fever, we treat the breathing difficulties with extra oxygen but there is no specific medicine like an anti-viral drug that targets the MERScoronavirus. And so that is what is being done here and what’s’ being done around the world. We know that some people are doing some research into particular anti-viral drugs but there is no recommended specific treatment at this point other than the supportive or non-specific care. So I think we have time for the last question, Laurel?
OPERATOR: Certainly, our final question comes from Kyle Thomas. Your line is open, please state your affiliation.
KYLE THOMAS: Hi, this is WTHR, the NBC station in Indianapolis. I know you can’t give a specific facility but I’m wondering if you can give us a city or region of Indiana where this patient is located.
ANNE SCHUCHAT: Thank you for that repeated question. I can tell you that the patient’s hospitalized in Indiana. We do need clinicians around the country not just in Indiana to be on the alert in terms of travel associated severe respiratory illness. We think an active investigation in Indiana is going to help us understand what, if any risk there is, beyond the individual patient. I really want to thank everybody for participating in the conference call. We have been talking about how interconnected the world is and how new diseases can be just a plane ride away. The first U.S. importation of MERScoronavirus represents a very low risk to the general public. Public health authorities in Indiana and surrounding areas are doing an active investigation to make sure we can control this condition. We will update as additional information occurs. I do want to remind people that at CDC’s website, CDC.gov and at the Indiana health department website, we will be posting a lot more information and trying to keep that updated. We will hold additional press conferences if important changes occur. Thank you so much for participating. Tom?
TOM SKINNER: Thank you everyone, and thank you Laurel, for participating. Those who have follow up questions or need additional information can call the CDC press office at 404-639-3286. This concludes our call. Thank you very much.
OPERATOR: That does conclude today’s presentation. Thank you all for joining. You may now disconnect.